02123nas a2200421   4500000000100000008004100001260001300042653001500055653001000070653000900080653001000089653001600099653001200115653003000127653001100157653002300168653002500191653002800216653002500244653001600269653002400285653001300309653001600322100001700338700001500355700002200370700001100392700001500403700001500418700001300433245014800446856004800594300000900642490001600651050002000667520100000687022001401687       2012                            d  c2012 Dec10aAdolescent10aAdult10aAged10aChild10aClofazimine10aDapsone10aDrug Therapy, Combination10aHumans10aLeprostatic Agents10aLeprosy, lepromatous10aLeprosy, Multibacillary10aLeprosy, Tuberculoid10aMiddle Aged10aProspective Studies10aRifampin10aYoung Adult1 aGonçalves H1 aPontes MAA1 aBührer-Sékula S1 aCruz R1 aAlmeida PC1 aMoraes MEA1 aPenna GO00aBrazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects.  uhttp://www.scielo.br/pdf/mioc/v107s1/13.pdf  a74-80 v107 Suppl 1  aCONϚALVES 20123 a<p>This study sought to verify the correlation between leprosy types and the adverse effects of treatment drugs. This quantitative, prospective, nested study was developed at the Dona Libânia Dermatology Centre in Fortaleza, Brazil. Data were collected from November 2007-November 2008. During this period, 818 leprosy patients were diagnosed and began treatment. Forty patients with tuberculoid leprosy (TT) were selected. Twenty patients followed a standard therapy of dapsone and rifampicin and 20 were administered dapsone, rifampicin and clofazimine (U-MDT). Twenty patients with borderline lepromatous (BL) and lepromatous leprosy (LL) were also selected and treated with U-MDT. All of the subjects received six doses. With the exception of haemolytic anaemia, there was a low incidence of adverse effects in all the groups. We did not observe any differences in the incidence of haemolytic anaemia or other side effects across groups of patients with TT, BL or LL treated with U-MDT.</p>  a1678-8060